Additionally, it has been demonstrated that BC patients with FGFR3 alterations are more sensitive to the treatment of the pan-FGFR inhibitor, erdafitinib (16); under a consensus molecular classification, these kinds of patients are considered to be highly enriched in the luminal subtype, showing poorer response to immune checkpoint inhibitors (ICIs) (17, 18). The gene discussed is FGFR3; the disease is breast cancer.